U.S. medical device manufacturer Medtronic has agreed to buy Ireland-based competitor Covidien for $42.9 billion in cash and stock.
The combined company would have its executive offices in Dublin, where it could benefit from Ireland's lower corporate tax rates. But the merged company would continue to operate in Minneapolis, where Medtronic employs more than 8,000, the companies said late Sunday in a statement.
Such deals which allow companies to shift profits out of the country have been heavily criticized by legislators in the U.S. and EU and the EU has begun investigating ways that companies such as Apple and Starbucks avoid paying taxes.
- Pfizer merger plan raises issue of corporate tax shifting
- EU antitrust regulator investigates Apple, Starbucks, Fiat tax agreements
Medtronic is paying a 29 per cent premium on Covidien's stock price as of Friday. The shares had closed at $72.02 on the New York Stock Exchange.
Shares of both companies surged in premarket trading Monday.
The deal is the latest in a series of acquisitions by medical-device manufacturers. The companies are seeking to expand their offerings and contain costs in response to price curbs forced by the U.S. new health care law.
In April, Zimmer Holdings, an orthopedic device maker, announced that it was buying Biomet in a $13-billion deal.
Medtronic makes pacemakers and insulin pumps, among other products. Covidien specializes in surgical equipment.
As a result of savings from the deal, Medtronic said it would spend an additional $10 billion over the next decade in investments, acquisitions and research and development in the United States.
"The medical technology industry is critical to the U.S. economy, and we will continue to invest and innovate and create well-paying jobs," Omar Ishrak, Medtronic's CEO, said in a statement.
In premarket trading Monday, Covidien shares climbed $22.68, or 31.5 percent, to $94.70 while Medtronic shares gained $4.16, or 6.9 percent, to $64.86.
Efforts by domestic companies to use mergers to reincorporate overseas for tax reasons have raised concern among some U.S. lawmakers. Ireland taxes corporate income at 12.5 percent, compared with a top marginal rate of 39.6 percent in the United States, according to the tax advisory firm KPMG.
Drug-maker Pfizer recently tried unsuccessfully to acquire U.K.-based Astra-Zeneca. The banana-seller Chiquita agreed to buy an Irish firm, Fyffes, in March.
Sen. Carl Levin, D-Michigan, and 13 other senators introduced a bill in May to restrict the deals.
"These transactions are about tax avoidance, plain and simple," Levin said in a statement. "Our legislation would clamp down on this loophole to prevent corporations from shifting their tax burden onto their competitors and average Americans."